Grant of Interim Extension of the Term of U.S. Patent No. 7,524,879; Vernakalant Hydrochloride, 62714 [2020-21966]

Download as PDF 62714 Federal Register / Vol. 85, No. 193 / Monday, October 5, 2020 / Notices 35 U.S.C. 156(d)(5) for a second interim extension of the term of the ’699 patent. The ’699 patent claims a method of using a veterinary biological product in the cancer immunotherapy treatment known by the tradename ECI® (ELIAS Cancer Immunotherapy). The application for interim patent term extension indicates that an application for a license for the veterinary biological product was submitted under the VirusSerum-Toxin Act and is currently undergoing regulatory review by the United States Department of Agriculture, Center for Veterinary Biologics. Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the ’699 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the extended expiration date of the ’699 patent, i.e., October 5, 2020, further interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. A second interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 6,406,699 is granted for a period of one year from the extended expiration date of the ’699 patent. [Docket No. PTO–P–2020–0048] 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent. On July 14, 2020, Correvio International Sa`rl, the owner of record of the ‘879 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the ‘879 patent. The ‘879 patent claims a method of using the product vernakalant hydrochloride. The application for interim patent term extension indicates that New Drug Application No. 22–034 for vernakalant hydrochloride was submitted to the Food and Drug Administration (FDA) on December 19, 2006, and that the FDA’s review thereof is ongoing. Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the ‘879 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the original expiration date of the patent, i.e., October 6, 2020, interim extension of the ‘879 patent’s term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,5242,879 is granted for a period of one year from the original expiration date of the ‘879 patent. Grant of Interim Extension of the Term of U.S. Patent No. 7,524,879; Vernakalant Hydrochloride Robert Bahr, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. Robert Bahr, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. [FR Doc. 2020–21969 Filed 10–2–20; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF COMMERCE Patent and Trademark Office [FR Doc. 2020–21966 Filed 10–2–20; 8:45 am] United States Patent and Trademark Office, Department of Commerce. ACTION: Notice of interim patent term extension. AGENCY: jbell on DSKJLSW7X2PROD with NOTICES BILLING CODE 3510–16–P DEPARTMENT OF COMMERCE The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 7,524,879 (‘879 patent). FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–7728 or by email to raul.tamayo@uspto.gov. SUMMARY: VerDate Sep<11>2014 23:42 Oct 02, 2020 Jkt 253001 SUPPLEMENTARY INFORMATION: Patent and Trademark Office [Docket No. PTO–P–2020–0046] Grant of Interim Extension of the Term of U.S. Patent No. 7,057,053; Vernakalant Hydrochloride United States Patent and Trademark Office, Department of Commerce. AGENCY: PO 00000 Frm 00025 Fmt 4703 Sfmt 9990 Notice of interim patent term extension. ACTION: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 7,057,053 (‘053 patent). SUMMARY: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–7728 or by email to raul.tamayo@uspto.gov. FOR FURTHER INFORMATION CONTACT: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent. On July 14, 2020, Correvio International Sa`rl, the owner of record of the ‘053 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the ‘053 patent. The ‘053 patent claims the product vernakalant hydrochloride. The application for interim patent term extension indicates that New Drug Application No. 22–034 for vernakalant hydrochloride was submitted to the Food and Drug Administration (FDA) on December 19, 2006, and that the FDA’s review thereof is ongoing. Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the ‘053 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the original expiration date of the patent, i.e., October 16, 2020, interim extension of the ‘053 patent’s term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,057,053 is granted for a period of one year from the original expiration date of the ‘053 patent. SUPPLEMENTARY INFORMATION: Robert Bahr, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. [FR Doc. 2020–21963 Filed 10–2–20; 8:45 am] BILLING CODE 3510–16–P E:\FR\FM\05OCN1.SGM 05OCN1

Agencies

[Federal Register Volume 85, Number 193 (Monday, October 5, 2020)]
[Notices]
[Page 62714]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21966]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO-P-2020-0048]


Grant of Interim Extension of the Term of U.S. Patent No. 
7,524,879; Vernakalant Hydrochloride

AGENCY: United States Patent and Trademark Office, Department of 
Commerce.

ACTION: Notice of interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting a one-year interim extension of the term of U.S. Patent 
No. 7,524,879 (`879 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, 
Office of Patent Legal Administration, by telephone at 571-272-7728 or 
by email to [email protected].

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the 
term of a patent may be extended for a period of up to five years, if 
the patent claims a product, or a method of making or using a product, 
that has been subject to certain defined regulatory review. 35 U.S.C. 
156(d)(5) generally provides that the term of such a patent may be 
extended for no more than five interim periods of up to one year each, 
if the approval phase of the regulatory review period is reasonably 
expected to extend beyond the expiration date of the patent.
    On July 14, 2020, Correvio International S[agrave]rl, the owner of 
record of the `879 patent, timely filed an application under 35 U.S.C. 
156(d)(5) for an interim extension of the term of the `879 patent. The 
`879 patent claims a method of using the product vernakalant 
hydrochloride. The application for interim patent term extension 
indicates that New Drug Application No. 22-034 for vernakalant 
hydrochloride was submitted to the Food and Drug Administration (FDA) 
on December 19, 2006, and that the FDA's review thereof is ongoing.
    Review of the interim patent term extension application indicates 
that, except for permission to market or use the product commercially, 
the `879 patent would be eligible for an extension of the patent term 
under 35 U.S.C. 156. Because it appears the approval phase of the 
regulatory review period will continue beyond the original expiration 
date of the patent, i.e., October 6, 2020, interim extension of the 
`879 patent's term under 35 U.S.C. 156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 7,5242,879 is granted for a period of one year from the 
original expiration date of the `879 patent.

Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2020-21966 Filed 10-2-20; 8:45 am]
BILLING CODE 3510-16-P